Vireo Growth (VREOF) Non-Current Debt (2020 - 2026)
Vireo Growth (VREOF) posted Non-Current Debt of $197.3 million for Q1 2026, up 54.62% sequentially from $127.6 million in Q4 2025, and up 215.16% YoY from $62.6 million in Q1 2025.
Vireo Growth (VREOF) Non-Current Debt (2020 - 2026) Analysis & Trends
Vireo Growth has reported Non-Current Debt for 7 years, with the latest figure at $197.3 million in Q1 2026.
- Quarterly Non-Current Debt rose 215.16% year-over-year to $197.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $197.3 million (up 215.16% YoY) and the FY2025 annual result came in at $127.6 million, up 104.82% from the prior year.
- Non-Current Debt climbed to $197.3 million in Q1 2026 per VREOF's latest filing, from $127.6 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $197.3 million in Q1 2026 and troughed at $1.1 million in Q2 2024.
- A 5-year average of $63.6 million and a median of $56.0 million in 2023 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2023 and 2025: Non-Current Debt tumbled 91.82% in 2023, then jumped 7232.02% in 2025.
- Over 5 years, Non-Current Debt stood at $46.2 million in 2022, then jumped by 30.21% to $60.2 million in 2023, then grew by 3.45% to $62.3 million in 2024, then jumped by 104.82% to $127.6 million in 2025, then surged by 54.62% to $197.3 million in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $197.3 million, $127.6 million, and $131.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 130.00 Mn |
| 10 | Vireo Growth | 482.88 Mn | 340.58 Mn | 95.30 Mn | 257.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 197.30 Mn |
| Dec 31, 2025 | 127.60 Mn |
| Sep 30, 2025 | 131.67 Mn |
| Jun 30, 2025 | 82.21 Mn |
| Mar 31, 2025 | 62.60 Mn |
| Dec 31, 2024 | 62.30 Mn |
| Sep 30, 2024 | 56.83 Mn |
| Jun 30, 2024 | 1.12 Mn |
| Dec 31, 2023 | 60.22 Mn |
| Sep 30, 2023 | 4.06 Mn |
| Jun 30, 2023 | 3.90 Mn |
| Mar 31, 2023 | 55.16 Mn |
| Dec 31, 2022 | 46.25 Mn |
| Sep 30, 2022 | 49.61 Mn |
| Jun 30, 2022 | 45.85 Mn |
| Mar 31, 2022 | 31.21 Mn |
| Dec 31, 2021 | 27.33 Mn |
| Sep 30, 2021 | 20.52 Mn |
| Jun 30, 2021 | 18.53 Mn |
| Mar 31, 2021 | 17.65 Mn |